> For your information...

> http://www.reuters.com/article/marketsNews/idCNSP7332220091105?rpc=44

> So if Hong Kong is paying $10 a dose for 3 million doses and Sinovac
> is supplying 65 million doses of h1n1 vaccine to the Chinese Gov.,
> with tax credits, that equals 65 million x $10 and an unbelievable 650
> million dollars. Their previous revenue guidance was revised up from
> 60 million dollars to an "unknown" figure. The 60 million was
> previously revised up from 22 million. On Q2 SVA's return on equity
> was 17.7%. Reuters has projected an EPS of .07 cents for Q3. Q2's EPS
> was .14. Is my belief an EPS of .49 for Q3 realistic? If someone comes
> up with a more exact EPS guess, I'd like to see it. The unknown is how
> many doses of h1n1 will SVA receive payment for in this quarter. I
> believe a partial order payment was paid by the Chinese Gov. for the
> 65 million doses ordered and the remaining (70%?) will be paid upon
> delivery. So a ballpark guess is 50% of the revenue on 65 million
> doses will be reported this quarter.

> On Nov 5, 3:50 pm, David <david.dodd...@gmail.com> wrote:

> > For your information...

> >http://www.reuters.com/article/marketsNews/idCNSP7332220091105?rpc=44- Hide quoted text -

> - Show quoted text -

> The Chinese govt is paying around $3 per shot, and the calculation
> should be based on doses already delivered(not 65 million). I wonder
> if SVA is going to take the hit for the development cost of the drug
> upfront or accrue it till year-end.  That would certain have an impact
> on the profitability for the quarter.

> On Nov 6, 7:58 am, wittle <jinsant...@gmail.com> wrote:

> > So if Hong Kong is paying $10 a dose for 3 million doses and Sinovac
> > is supplying 65 million doses of h1n1 vaccine to the Chinese Gov.,
> > with tax credits, that equals 65 million x $10 and an unbelievable 650
> > million dollars. Their previous revenue guidance was revised up from
> > 60 million dollars to an "unknown" figure. The 60 million was
> > previously revised up from 22 million. On Q2 SVA's return on equity
> > was 17.7%. Reuters has projected an EPS of .07 cents for Q3. Q2's EPS
> > was .14. Is my belief an EPS of .49 for Q3 realistic? If someone comes
> > up with a more exact EPS guess, I'd like to see it. The unknown is how
> > many doses of h1n1 will SVA receive payment for in this quarter. I
> > believe a partial order payment was paid by the Chinese Gov. for the
> > 65 million doses ordered and the remaining (70%?) will be paid upon
> > delivery. So a ballpark guess is 50% of the revenue on 65 million
> > doses will be reported this quarter.

> > On Nov 5, 3:50 pm, David <david.dodd...@gmail.com> wrote:

> > > For your information...

> > >http://www.reuters.com/article/marketsNews/idCNSP7332220091105?rpc=44... quoted text -

> > - Show quoted text -- Hide quoted text -

> - Show quoted text -

> The Chinese govt is paying around $3 per shot, and the calculation
> should be based on doses already delivered(not 65 million). I wonder
> if SVA is going to take the hit for the development cost of the drug
> upfront or accrue it till year-end.  That would certain have an impact
> on the profitability for the quarter.

> On Nov 6, 7:58 am, wittle <jinsant...@gmail.com> wrote:

> > So if Hong Kong is paying $10 a dose for 3 million doses and Sinovac
> > is supplying 65 million doses of h1n1 vaccine to the Chinese Gov.,
> > with tax credits, that equals 65 million x $10 and an unbelievable 650
> > million dollars. Their previous revenue guidance was revised up from
> > 60 million dollars to an "unknown" figure. The 60 million was
> > previously revised up from 22 million. On Q2 SVA's return on equity
> > was 17.7%. Reuters has projected an EPS of .07 cents for Q3. Q2's EPS
> > was .14. Is my belief an EPS of .49 for Q3 realistic? If someone comes
> > up with a more exact EPS guess, I'd like to see it. The unknown is how
> > many doses of h1n1 will SVA receive payment for in this quarter. I
> > believe a partial order payment was paid by the Chinese Gov. for the
> > 65 million doses ordered and the remaining (70%?) will be paid upon
> > delivery. So a ballpark guess is 50% of the revenue on 65 million
> > doses will be reported this quarter.

> > On Nov 5, 3:50 pm, David <david.dodd...@gmail.com> wrote:

> > > For your information...

> > >http://www.reuters.com/article/marketsNews/idCNSP7332220091105?rpc=44... quoted text -

> > - Show quoted text -

> There has to be some added incentives, tax credits, low interest
> loans, additional payment for development cost, given to SVA by the
> government. I've heard this $3 number, the price of two tootsie rolls.
> I don't believe that number will be validated in the end. Just making
> and moving the empty vials would cost $3 and the Chinese  gov. would
> never force a company to run in the red. No, SVA will probably be
> rewarded with free land and a new facility, besides a bunch of medals,
> for their heroic efforts.

> On Nov 5, 5:32 pm, tickerwatch <aileenn...@gmail.com> wrote:

> > The Chinese govt is paying around $3 per shot, and the calculation
> > should be based on doses already delivered(not 65 million). I wonder
> > if SVA is going to take the hit for the development cost of the drug
> > upfront or accrue it till year-end.  That would certain have an impact
> > on the profitability for the quarter.

> > On Nov 6, 7:58 am, wittle <jinsant...@gmail.com> wrote:

> > > So if Hong Kong is paying $10 a dose for 3 million doses and Sinovac
> > > is supplying 65 million doses of h1n1 vaccine to the Chinese Gov.,
> > > with tax credits, that equals 65 million x $10 and an unbelievable 650
> > > million dollars. Their previous revenue guidance was revised up from
> > > 60 million dollars to an "unknown" figure. The 60 million was
> > > previously revised up from 22 million. On Q2 SVA's return on equity
> > > was 17.7%. Reuters has projected an EPS of .07 cents for Q3. Q2's EPS
> > > was .14. Is my belief an EPS of .49 for Q3 realistic? If someone comes
> > > up with a more exact EPS guess, I'd like to see it. The unknown is how
> > > many doses of h1n1 will SVA receive payment for in this quarter. I
> > > believe a partial order payment was paid by the Chinese Gov. for the
> > > 65 million doses ordered and the remaining (70%?) will be paid upon
> > > delivery. So a ballpark guess is 50% of the revenue on 65 million
> > > doses will be reported this quarter.

> > > On Nov 5, 3:50 pm, David <david.dodd...@gmail.com> wrote:

> > > > For your information...

> > > >http://www.reuters.com/article/marketsNews/idCNSP7332220091105?rpc=44... text -

> > > - Show quoted text -

> For those wondering about Sinovac's future plans, here's an
> interesting article from BIZCHINA

> BIZCHINA> Top Biz News

> Sinovac Biotech to transfer quote to NASDAQ from Amex

> By Ding Qingfen (China Daily)
> Updated: 2009-11-05 08:44

> Sinovac Biotech Ltd, China's first officially approved H1N1 flu
> vaccine maker, announced yesterday it would transfer its stock
> exchange listing to the NASDAQ Global Market from NYSE Amex in a bid
> to raise more funds and become a leading vaccine producer.

> The spread of H1N1 flu in China has benefited Sinovac, which is
> China's second largest H1N1 flu vaccine producer in volume terms. Its
> shares are expected to start trading on the NASDAQ by mid-November.

> The funds raised will be injected into expanding vaccine production
> capacity, strengthening research capability and conducting mergers and
> acquisitions, said corporate executives.

> "Sinovac expects to be a leading international vaccine producer
> through quality and reasonably-priced products to Chinese and others
> in need," said Yin Weidong, chairman of Sinovac Biotech Ltd.

> Sinovac has an annual H1N1 vaccine output to meet the needs of 30
> million people, and it will expand the capacity for both flu and other
> diseases, Yin said.

> Besides, Sinovac will also increase research and development spending
> from the current 5 to 10 percent, he said.

> The company has started developing a vaccine for hand, foot and mouth
> disease, the first to do so in China, and is expected to apply for
> clinical trials next year.

> Sinovac Biotech got listed on the NYSE Amex late in 2004, and had
> planned for the transfer for long, but could not meet the market
> requirements by NASDAQ due to its low share price, said Helen G Yang,
> manager of the international business department at Sinovac Biotech.

> When its shares started surging since early this year after the
> outbreak of the H1N1 influenza, the company began to communicate with
> the NASDAQ bourse in August, she said.

> Since it started developing the H1N1 vaccine in early June, Sinovac's
> share price has more than tripled during the past five months, from
> around $2. On Tuesday, its stock closed at $7.91.

> Compared with their share prices three months ago, the Hualan
> Biological Engineering and Tiantan Biological shares had risen by 200
> and 150 percent, respectively, at the end of October.

> During the roadshow in late September, Sinovac was warmly welcomed by
> the NASDAQ market. "I felt so surprised to see the strong recognition
> of a Chinese vaccine producer," said Yin.

> "The H1N1 flu and Sinovac's good performance during the outbreak have
> increased the speed of its transfer to the NASDAQ."

> Sinovac Biotech, established in 2001, was the first company in the
> world to announce preliminary clinical trials of the vaccine and the
> first to get approval for production from the Chinese government in
> late August.

> The company has won three orders for 11.49 million people, the second
> largest supplier after Hualan Biological among the eight Chinese H1N1
> flu vaccine producers.

> As on Nov 1, the Chinese mainland had reported 47,500 H1N1 cases in 31
> provinces and regions. It is estimated that 390 million Chinese need
> to get vaccinated, but the nation had only ordered vaccines for 70
> million people until October.

> Sinovac said it expected to get more orders, and was speeding up
> production, but "the benefits from the H1N1 flu vaccine are short-
> term. What we are targeting is to become a leading vaccine producer
> worldwide by leveraging our growing brand awareness," Yin said.

> China is now the third largest vaccine market with a size of $1
> billion annually.

> On Nov 5, 6:58 pm, wittle <jinsant...@gmail.com> wrote:

> > There has to be some added incentives, tax credits, low interest
> > loans, additional payment for development cost, given to SVA by the
> > government. I've heard this $3 number, the price of two tootsie rolls.
> > I don't believe that number will be validated in the end. Just making
> > and moving the empty vials would cost $3 and the Chinese  gov. would
> > never force a company to run in the red. No, SVA will probably be
> > rewarded with free land and a new facility, besides a bunch of medals,
> > for their heroic efforts.

> > On Nov 5, 5:32 pm, tickerwatch <aileenn...@gmail.com> wrote:

> > > The Chinese govt is paying around $3 per shot, and the calculation
> > > should be based on doses already delivered(not 65 million). I wonder
> > > if SVA is going to take the hit for the development cost of the drug
> > > upfront or accrue it till year-end.  That would certain have an impact
> > > on the profitability for the quarter.

> > > On Nov 6, 7:58 am, wittle <jinsant...@gmail.com> wrote:

> > > > So if Hong Kong is paying $10 a dose for 3 million doses and Sinovac
> > > > is supplying 65 million doses of h1n1 vaccine to the Chinese Gov.,
> > > > with tax credits, that equals 65 million x $10 and an unbelievable 650
> > > > million dollars. Their previous revenue guidance was revised up from
> > > > 60 million dollars to an "unknown" figure. The 60 million was
> > > > previously revised up from 22 million. On Q2 SVA's return on equity
> > > > was 17.7%. Reuters has projected an EPS of .07 cents for Q3. Q2's EPS
> > > > was .14. Is my belief an EPS of .49 for Q3 realistic? If someone comes
> > > > up with a more exact EPS guess, I'd like to see it. The unknown is how
> > > > many doses of h1n1 will SVA receive payment for in this quarter. I
> > > > believe a partial order payment was paid by the Chinese Gov. for the
> > > > 65 million doses ordered and the remaining (70%?) will be paid upon
> > > > delivery. So a ballpark guess is 50% of the revenue on 65 million
> > > > doses will be reported this quarter.

> > > > On Nov 5, 3:50 pm, David <david.dodd...@gmail.com> wrote:

> > > > > For your information...

> > > > >http://www.reuters.com/article/marketsNews/idCNSP7332220091105?rpc=44... -

> > > > - Show quoted text -

> For those wondering about Sinovac's future plans, here's an
> interesting article from BIZCHINA

> BIZCHINA> Top Biz News

> Sinovac Biotech to transfer quote to NASDAQ from Amex

> By Ding Qingfen (China Daily)
> Updated: 2009-11-05 08:44

> Sinovac Biotech Ltd, China's first officially approved H1N1 flu
> vaccine maker, announced yesterday it would transfer its stock
> exchange listing to the NASDAQ Global Market from NYSE Amex in a bid
> to raise more funds and become a leading vaccine producer.

> The spread of H1N1 flu in China has benefited Sinovac, which is
> China's second largest H1N1 flu vaccine producer in volume terms. Its
> shares are expected to start trading on the NASDAQ by mid-November.

> The funds raised will be injected into expanding vaccine production
> capacity, strengthening research capability and conducting mergers and
> acquisitions, said corporate executives.

> "Sinovac expects to be a leading international vaccine producer
> through quality and reasonably-priced products to Chinese and others
> in need," said Yin Weidong, chairman of Sinovac Biotech Ltd.

> Sinovac has an annual H1N1 vaccine output to meet the needs of 30
> million people, and it will expand the capacity for both flu and other
> diseases, Yin said.

> Besides, Sinovac will also increase research and development spending
> from the current 5 to 10 percent, he said.

> The company has started developing a vaccine for hand, foot and mouth
> disease, the first to do so in China, and is expected to apply for
> clinical trials next year.

> Sinovac Biotech got listed on the NYSE Amex late in 2004, and had
> planned for the transfer for long, but could not meet the market
> requirements by NASDAQ due to its low share price, said Helen G Yang,
> manager of the international business department at Sinovac Biotech.

> When its shares started surging since early this year after the
> outbreak of the H1N1 influenza, the company began to communicate with
> the NASDAQ bourse in August, she said.

> Since it started developing the H1N1 vaccine in early June, Sinovac's
> share price has more than tripled during the past five months, from
> around $2. On Tuesday, its stock closed at $7.91.

> Compared with their share prices three months ago, the Hualan
> Biological Engineering and Tiantan Biological shares had risen by 200
> and 150 percent, respectively, at the end of October.

> During the roadshow in late September, Sinovac was warmly welcomed by
> the NASDAQ market. "I felt so surprised to see the strong recognition
> of a Chinese vaccine producer," said Yin.

> "The H1N1 flu and Sinovac's good performance during the outbreak have
> increased the speed of its transfer to the NASDAQ."

> Sinovac Biotech, established in 2001, was the first company in the
> world to announce preliminary clinical trials of the vaccine and the
> first to get approval for production from the Chinese government in
> late August.

> The company has won three orders for 11.49 million people, the second
> largest supplier after Hualan Biological among the eight Chinese H1N1
> flu vaccine producers.

> As on Nov 1, the Chinese mainland had reported 47,500 H1N1 cases in 31
> provinces and regions. It is estimated that 390 million Chinese need
> to get vaccinated, but the nation had only ordered vaccines for 70
> million people until October.

> Sinovac said it expected to get more orders, and was speeding up
> production, but "the benefits from the H1N1 flu vaccine are short-
> term. What we are targeting is to become a leading vaccine producer
> worldwide by leveraging our growing brand awareness," Yin said.

> China is now the third largest vaccine market with a size of $1
> billion annually.

> On Nov 5, 6:58 pm, wittle <jinsant...@gmail.com> wrote:

> > There has to be some added incentives, tax credits, low interest
> > loans, additional payment for development cost, given to SVA by the
> > government. I've heard this $3 number, the price of two tootsie rolls.
> > I don't believe that number will be validated in the end. Just making
> > and moving the empty vials would cost $3 and the Chinese  gov. would
> > never force a company to run in the red. No, SVA will probably be
> > rewarded with free land and a new facility, besides a bunch of medals,
> > for their heroic efforts.

> > On Nov 5, 5:32 pm, tickerwatch <aileenn...@gmail.com> wrote:

> > > The Chinese govt is paying around $3 per shot, and the calculation
> > > should be based on doses already delivered(not 65 million). I wonder
> > > if SVA is going to take the hit for the development cost of the drug
> > > upfront or accrue it till year-end.  That would certain have an impact
> > > on the profitability for the quarter.

> > > On Nov 6, 7:58 am, wittle <jinsant...@gmail.com> wrote:

> > > > So if Hong Kong is paying $10 a dose for 3 million doses and Sinovac
> > > > is supplying 65 million doses of h1n1 vaccine to the Chinese Gov.,
> > > > with tax credits, that equals 65 million x $10 and an unbelievable 650
> > > > million dollars. Their previous revenue guidance was revised up from
> > > > 60 million dollars to an "unknown" figure. The 60 million was
> > > > previously revised up from 22 million. On Q2 SVA's return on equity
> > > > was 17.7%. Reuters has projected an EPS of .07 cents for Q3. Q2's EPS
> > > > was .14. Is my belief an EPS of .49 for Q3 realistic? If someone comes
> > > > up with a more exact EPS guess, I'd like to see it. The unknown is how
> > > > many doses of h1n1 will SVA receive payment for in this quarter. I
> > > > believe a partial order payment was paid by the Chinese Gov. for the
> > > > 65 million doses ordered and the remaining (70%?) will be paid upon
> > > > delivery. So a ballpark guess is 50% of the revenue on 65 million
> > > > doses will be reported this quarter.

> > > > On Nov 5, 3:50 pm, David <david.dodd...@gmail.com> wrote:

> > > > > For your information...

> > > > >http://www.reuters.com/article/marketsNews/idCNSP7332220091105?rpc=44... -

> > > > - Show quoted text -

> I found this information with a link on Yahoo Finance"

> From ClinicalTrials.gov
> A Service of the U.S. National Institute of Health

> A Clinical Trial With Influenza A/H1N1 Vaccines
> This study has been completed.
> First Received: August 10, 2009 Last Updated: October 28, 2009 History
> of Changes
> Sponsor: Sinovac Biotech Co., Ltd
> Information provided by: Sinovac Biotech Co., Ltd
> ClinicalTrials.gov Identifier: NCT00956111
> Purpose

> A single center, stratified, randomized and double-blind phase IV
> clinical trial is to be conducted in healthy elders (equal to or more
> than 61 years), adults (18-60 years), adolescents (12-17 years) and
> children (3-11 years) to evaluate the safety and immunogenicity of
> Sinovac's split-virion or whole-virion novel influenza A (H1N1)
> vaccines.

> Condition Intervention Phase
> Influenza
> Biological: split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose
> Biological: split-virion, adjuvanted H1N1 vaccine of 15 μg per dose
> Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg per
> dose
> Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg per
> dose
> Biological: whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose
> Biological: whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose
> Biological: placebo control
> Phase IV

> Study Type: Interventional
> Study Design: Prevention, Randomized, Double Blind (Subject,
> Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel
> Assignment, Safety/Efficacy Study
> Official Title: A Double-blind, Randomized, Stratified and Controlled
> Clinical Trial With Split-virion and Whole-virion, Adjuvanted and Non-
> adjuvanted Influenza A/H1N1 Vaccines in Healthy Adults, Elders,
> Adolescents and Children

> http://clinicaltrials.gov/ct2/show/NCT00...

> On Nov 5, 7:11 pm, sakalas91 <boris.baku...@gmail.com> wrote:

> > For those wondering about Sinovac's future plans, here's an
> > interesting article from BIZCHINA

> > BIZCHINA> Top Biz News

> > Sinovac Biotech to transfer quote to NASDAQ from Amex

> > By Ding Qingfen (China Daily)
> > Updated: 2009-11-05 08:44

> > Sinovac Biotech Ltd, China's first officially approved H1N1 flu
> > vaccine maker, announced yesterday it would transfer its stock
> > exchange listing to the NASDAQ Global Market from NYSE Amex in a bid
> > to raise more funds and become a leading vaccine producer.

> > The spread of H1N1 flu in China has benefited Sinovac, which is
> > China's second largest H1N1 flu vaccine producer in volume terms. Its
> > shares are expected to start trading on the NASDAQ by mid-November.

> > The funds raised will be injected into expanding vaccine production
> > capacity, strengthening research capability and conducting mergers and
> > acquisitions, said corporate executives.

> > "Sinovac expects to be a leading international vaccine producer
> > through quality and reasonably-priced products to Chinese and others
> > in need," said Yin Weidong, chairman of Sinovac Biotech Ltd.

> > Sinovac has an annual H1N1 vaccine output to meet the needs of 30
> > million people, and it will expand the capacity for both flu and other
> > diseases, Yin said.

> > Besides, Sinovac will also increase research and development spending
> > from the current 5 to 10 percent, he said.

> > The company has started developing a vaccine for hand, foot and mouth
> > disease, the first to do so in China, and is expected to apply for
> > clinical trials next year.

> > Sinovac Biotech got listed on the NYSE Amex late in 2004, and had
> > planned for the transfer for long, but could not meet the market
> > requirements by NASDAQ due to its low share price, said Helen G Yang,
> > manager of the international business department at Sinovac Biotech.

> > When its shares started surging since early this year after the
> > outbreak of the H1N1 influenza, the company began to communicate with
> > the NASDAQ bourse in August, she said.

> > Since it started developing the H1N1 vaccine in early June, Sinovac's
> > share price has more than tripled during the past five months, from
> > around $2. On Tuesday, its stock closed at $7.91.

> > Compared with their share prices three months ago, the Hualan
> > Biological Engineering and Tiantan Biological shares had risen by 200
> > and 150 percent, respectively, at the end of October.

> > During the roadshow in late September, Sinovac was warmly welcomed by
> > the NASDAQ market. "I felt so surprised to see the strong recognition
> > of a Chinese vaccine producer," said Yin.

> > "The H1N1 flu and Sinovac's good performance during the outbreak have
> > increased the speed of its transfer to the NASDAQ."

> > Sinovac Biotech, established in 2001, was the first company in the
> > world to announce preliminary clinical trials of the vaccine and the
> > first to get approval for production from the Chinese government in
> > late August.

> > The company has won three orders for 11.49 million people, the second
> > largest supplier after Hualan Biological among the eight Chinese H1N1
> > flu vaccine producers.

> > As on Nov 1, the Chinese mainland had reported 47,500 H1N1 cases in 31
> > provinces and regions. It is estimated that 390 million Chinese need
> > to get vaccinated, but the nation had only ordered vaccines for 70
> > million people until October.

> > Sinovac said it expected to get more orders, and was speeding up
> > production, but "the benefits from the H1N1 flu vaccine are short-
> > term. What we are targeting is to become a leading vaccine producer
> > worldwide by leveraging our growing brand awareness," Yin said.

> > China is now the third largest vaccine market with a size of $1
> > billion annually.

> > On Nov 5, 6:58 pm, wittle <jinsant...@gmail.com> wrote:

> > > There has to be some added incentives, tax credits, low interest
> > > loans, additional payment for development cost, given to SVA by the
> > > government. I've heard this $3 number, the price of two tootsie rolls.
> > > I don't believe that number will be validated in the end. Just making
> > > and moving the empty vials would cost $3 and the Chinese  gov. would
> > > never force a company to run in the red. No, SVA will probably be
> > > rewarded with free land and a new facility, besides a bunch of medals,
> > > for their heroic efforts.

> > > On Nov 5, 5:32 pm, tickerwatch <aileenn...@gmail.com> wrote:

> > > > The Chinese govt is paying around $3 per shot, and the calculation
> > > > should be based on doses already delivered(not 65 million). I wonder
> > > > if SVA is going to take the hit for the development cost of the drug
> > > > upfront or accrue it till year-end.  That would certain have an impact
> > > > on the profitability for the quarter.

> > > > On Nov 6, 7:58 am, wittle <jinsant...@gmail.com> wrote:

> > > > > So if Hong Kong is paying $10 a dose for 3 million doses and Sinovac
> > > > > is supplying 65 million doses of h1n1 vaccine to the Chinese Gov.,
> > > > > with tax credits, that equals 65 million x $10 and an unbelievable 650
> > > > > million dollars. Their previous revenue guidance was revised up from
> > > > > 60 million dollars to an "unknown" figure. The 60 million was
> > > > > previously revised up from 22 million. On Q2 SVA's return on equity
> > > > > was 17.7%. Reuters has projected an EPS of .07 cents for Q3. Q2's EPS
> > > > > was .14. Is my belief an EPS of .49 for Q3 realistic? If someone comes
> > > > > up with a more exact EPS guess, I'd like to see it. The unknown is how
> > > > > many doses of h1n1 will SVA receive payment for in this quarter. I
> > > > > believe a partial order payment was paid by the Chinese Gov. for the
> > > > > 65 million doses ordered and the remaining (70%?) will be paid upon
> > > > > delivery. So a ballpark guess is 50% of the revenue on 65 million
> > > > > doses will be reported this quarter.

> > > > > On Nov 5, 3:50 pm, David <david.dodd...@gmail.com> wrote:

> > > > > > For your information...

> > > > > >http://www.reuters.com/article/marketsNews/idCNSP7332220091105?rpc=44...

> > > > > - Show quoted text -

> For some reason, the link does not lead to the study.  However, the
> study can be accessed on clinicaltrials.gov by entering the following
> number in the search box:  NCT00956111.  I'm not sure of the
> ramifications of the information above.  Anybody know?

> On Nov 5, 7:23 pm, sakalas91 <boris.baku...@gmail.com> wrote:

> > I found this information with a link on Yahoo Finance"

> > From ClinicalTrials.gov
> > A Service of the U.S. National Institute of Health

> > A Clinical Trial With Influenza A/H1N1 Vaccines
> > This study has been completed.
> > First Received: August 10, 2009 Last Updated: October 28, 2009 History
> > of Changes
> > Sponsor: Sinovac Biotech Co., Ltd
> > Information provided by: Sinovac Biotech Co., Ltd
> > ClinicalTrials.gov Identifier: NCT00956111
> > Purpose

> > A single center, stratified, randomized and double-blind phase IV
> > clinical trial is to be conducted in healthy elders (equal to or more
> > than 61 years), adults (18-60 years), adolescents (12-17 years) and
> > children (3-11 years) to evaluate the safety and immunogenicity of
> > Sinovac's split-virion or whole-virion novel influenza A (H1N1)
> > vaccines.

> > Condition Intervention Phase
> > Influenza
> > Biological: split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose
> > Biological: split-virion, adjuvanted H1N1 vaccine of 15 μg per dose
> > Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg per
> > dose
> > Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg per
> > dose
> > Biological: whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose
> > Biological: whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose
> > Biological: placebo control
> > Phase IV

> > Study Type: Interventional
> > Study Design: Prevention, Randomized, Double Blind (Subject,
> > Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel
> > Assignment, Safety/Efficacy Study
> > Official Title: A Double-blind, Randomized, Stratified and Controlled
> > Clinical Trial With Split-virion and Whole-virion, Adjuvanted and Non-
> > adjuvanted Influenza A/H1N1 Vaccines in Healthy Adults, Elders,
> > Adolescents and Children

> >http://clinicaltrials.gov/ct2/show/NCT00...

> > On Nov 5, 7:11 pm, sakalas91 <boris.baku...@gmail.com> wrote:

> > > For those wondering about Sinovac's future plans, here's an
> > > interesting article from BIZCHINA

> > > BIZCHINA> Top Biz News

> > > Sinovac Biotech to transfer quote to NASDAQ from Amex

> > > By Ding Qingfen (China Daily)
> > > Updated: 2009-11-05 08:44

> > > Sinovac Biotech Ltd, China's first officially approved H1N1 flu
> > > vaccine maker, announced yesterday it would transfer its stock
> > > exchange listing to the NASDAQ Global Market from NYSE Amex in a bid
> > > to raise more funds and become a leading vaccine producer.

> > > The spread of H1N1 flu in China has benefited Sinovac, which is
> > > China's second largest H1N1 flu vaccine producer in volume terms. Its
> > > shares are expected to start trading on the NASDAQ by mid-November.

> > > The funds raised will be injected into expanding vaccine production
> > > capacity, strengthening research capability and conducting mergers and
> > > acquisitions, said corporate executives.

> > > "Sinovac expects to be a leading international vaccine producer
> > > through quality and reasonably-priced products to Chinese and others
> > > in need," said Yin Weidong, chairman of Sinovac Biotech Ltd.

> > > Sinovac has an annual H1N1 vaccine output to meet the needs of 30
> > > million people, and it will expand the capacity for both flu and other
> > > diseases, Yin said.

> > > Besides, Sinovac will also increase research and development spending
> > > from the current 5 to 10 percent, he said.

> > > The company has started developing a vaccine for hand, foot and mouth
> > > disease, the first to do so in China, and is expected to apply for
> > > clinical trials next year.

> > > Sinovac Biotech got listed on the NYSE Amex late in 2004, and had
> > > planned for the transfer for long, but could not meet the market
> > > requirements by NASDAQ due to its low share price, said Helen G Yang,
> > > manager of the international business department at Sinovac Biotech.

> > > When its shares started surging since early this year after the
> > > outbreak of the H1N1 influenza, the company began to communicate with
> > > the NASDAQ bourse in August, she said.

> > > Since it started developing the H1N1 vaccine in early June, Sinovac's
> > > share price has more than tripled during the past five months, from
> > > around $2. On Tuesday, its stock closed at $7.91.

> > > Compared with their share prices three months ago, the Hualan
> > > Biological Engineering and Tiantan Biological shares had risen by 200
> > > and 150 percent, respectively, at the end of October.

> > > During the roadshow in late September, Sinovac was warmly welcomed by
> > > the NASDAQ market. "I felt so surprised to see the strong recognition
> > > of a Chinese vaccine producer," said Yin.

> > > "The H1N1 flu and Sinovac's good performance during the outbreak have
> > > increased the speed of its transfer to the NASDAQ."

> > > Sinovac Biotech, established in 2001, was the first company in the
> > > world to announce preliminary clinical trials of the vaccine and the
> > > first to get approval for production from the Chinese government in
> > > late August.

> > > The company has won three orders for 11.49 million people, the second
> > > largest supplier after Hualan Biological among the eight Chinese H1N1
> > > flu vaccine producers.

> > > As on Nov 1, the Chinese mainland had reported 47,500 H1N1 cases in 31
> > > provinces and regions. It is estimated that 390 million Chinese need
> > > to get vaccinated, but the nation had only ordered vaccines for 70
> > > million people until October.

> > > Sinovac said it expected to get more orders, and was speeding up
> > > production, but "the benefits from the H1N1 flu vaccine are short-
> > > term. What we are targeting is to become a leading vaccine producer
> > > worldwide by leveraging our growing brand awareness," Yin said.

> > > China is now the third largest vaccine market with a size of $1
> > > billion annually.

> > > On Nov 5, 6:58 pm, wittle <jinsant...@gmail.com> wrote:

> > > > There has to be some added incentives, tax credits, low interest
> > > > loans, additional payment for development cost, given to SVA by the
> > > > government. I've heard this $3 number, the price of two tootsie rolls.
> > > > I don't believe that number will be validated in the end. Just making
> > > > and moving the empty vials would cost $3 and the Chinese  gov. would
> > > > never force a company to run in the red. No, SVA will probably be
> > > > rewarded with free land and a new facility, besides a bunch of medals,
> > > > for their heroic efforts.

> > > > On Nov 5, 5:32 pm, tickerwatch <aileenn...@gmail.com> wrote:

> > > > > The Chinese govt is paying around $3 per shot, and the calculation
> > > > > should be based on doses already delivered(not 65 million). I wonder
> > > > > if SVA is going to take the hit for the development cost of the drug
> > > > > upfront or accrue it till year-end.  That would certain have an impact
> > > > > on the profitability for the quarter.

> > > > > On Nov 6, 7:58 am, wittle <jinsant...@gmail.com> wrote:

> > > > > > So if Hong Kong is paying $10 a dose for 3 million doses and Sinovac
> > > > > > is supplying 65 million doses of h1n1 vaccine to the Chinese Gov.,
> > > > > > with tax credits, that equals 65 million x $10 and an unbelievable 650
> > > > > > million dollars. Their previous revenue guidance was revised up from
> > > > > > 60 million dollars to an "unknown" figure. The 60 million was
> > > > > > previously revised up from 22 million. On Q2 SVA's return on equity
> > > > > > was 17.7%. Reuters has projected an EPS of .07 cents for Q3. Q2's EPS
> > > > > > was .14. Is my belief an EPS of .49 for Q3 realistic? If someone comes
> > > > > > up with a more exact EPS guess, I'd like to see it. The unknown is how
> > > > > > many doses of h1n1 will SVA receive payment for in this quarter. I
> > > > > > believe a partial order payment was paid by the Chinese Gov. for the
> > > > > > 65 million doses ordered and the remaining (70%?) will be paid upon
> > > > > > delivery. So a ballpark guess is 50% of the revenue on 65 million
> > > > > > doses will be reported this quarter.

> > > > > > On Nov 5, 3:50 pm, David <david.dodd...@gmail.com> wrote:

> > > > > > > For your information...

> > > > > > >http://www.reuters.com/article/marketsNews/idCNSP7332220091105?rpc=44...

> > > > > > - Show quoted text -- Hide quoted text -

> - Show quoted text -

> The study you refer to is testing a new dual vaccine, combining both
> seasonal and H1N1 flu, on different populations and in different doses
> to verify its efficacy and obtain the clinical data to get 'dual'
> vaccine approved for licence.

> Great news for SVA.

> An even STRONGER HOLD now ;-)
> Hold on to your hat, things are nearing take off.

> On 6 Nov, 02:18, sakalas91 <boris.baku...@gmail.com> wrote:

> > For some reason, the link does not lead to the study.  However, the
> > study can be accessed on clinicaltrials.gov by entering the following
> > number in the search box:  NCT00956111.  I'm not sure of the
> > ramifications of the information above.  Anybody know?

> > On Nov 5, 7:23 pm, sakalas91 <boris.baku...@gmail.com> wrote:

> > > I found this information with a link on Yahoo Finance"

> > > From ClinicalTrials.gov
> > > A Service of the U.S. National Institute of Health

> > > A Clinical Trial With Influenza A/H1N1 Vaccines
> > > This study has been completed.
> > > First Received: August 10, 2009 Last Updated: October 28, 2009 History
> > > of Changes
> > > Sponsor: Sinovac Biotech Co., Ltd
> > > Information provided by: Sinovac Biotech Co., Ltd
> > > ClinicalTrials.gov Identifier: NCT00956111
> > > Purpose

> > > A single center, stratified, randomized and double-blind phase IV
> > > clinical trial is to be conducted in healthy elders (equal to or more
> > > than 61 years), adults (18-60 years), adolescents (12-17 years) and
> > > children (3-11 years) to evaluate the safety and immunogenicity of
> > > Sinovac's split-virion or whole-virion novel influenza A (H1N1)
> > > vaccines.

> > > Condition Intervention Phase
> > > Influenza
> > > Biological: split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose
> > > Biological: split-virion, adjuvanted H1N1 vaccine of 15 μg per dose
> > > Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg per
> > > dose
> > > Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg per
> > > dose
> > > Biological: whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose
> > > Biological: whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose
> > > Biological: placebo control
> > > Phase IV

> > > Study Type: Interventional
> > > Study Design: Prevention, Randomized, Double Blind (Subject,
> > > Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel
> > > Assignment, Safety/Efficacy Study
> > > Official Title: A Double-blind, Randomized, Stratified and Controlled
> > > Clinical Trial With Split-virion and Whole-virion, Adjuvanted and Non-
> > > adjuvanted Influenza A/H1N1 Vaccines in Healthy Adults, Elders,
> > > Adolescents and Children

> > >http://clinicaltrials.gov/ct2/show/NCT00...

> > > On Nov 5, 7:11 pm, sakalas91 <boris.baku...@gmail.com> wrote:

> > > > For those wondering about Sinovac's future plans, here's an
> > > > interesting article from BIZCHINA

> > > > BIZCHINA> Top Biz News

> > > > Sinovac Biotech to transfer quote to NASDAQ from Amex

> > > > By Ding Qingfen (China Daily)
> > > > Updated: 2009-11-05 08:44

> > > > Sinovac Biotech Ltd, China's first officially approved H1N1 flu
> > > > vaccine maker, announced yesterday it would transfer its stock
> > > > exchange listing to the NASDAQ Global Market from NYSE Amex in a bid
> > > > to raise more funds and become a leading vaccine producer.

> > > > The spread of H1N1 flu in China has benefited Sinovac, which is
> > > > China's second largest H1N1 flu vaccine producer in volume terms. Its
> > > > shares are expected to start trading on the NASDAQ by mid-November.

> > > > The funds raised will be injected into expanding vaccine production
> > > > capacity, strengthening research capability and conducting mergers and
> > > > acquisitions, said corporate executives.

> > > > "Sinovac expects to be a leading international vaccine producer
> > > > through quality and reasonably-priced products to Chinese and others
> > > > in need," said Yin Weidong, chairman of Sinovac Biotech Ltd.

> > > > Sinovac has an annual H1N1 vaccine output to meet the needs of 30
> > > > million people, and it will expand the capacity for both flu and other
> > > > diseases, Yin said.

> > > > Besides, Sinovac will also increase research and development spending
> > > > from the current 5 to 10 percent, he said.

> > > > The company has started developing a vaccine for hand, foot and mouth
> > > > disease, the first to do so in China, and is expected to apply for
> > > > clinical trials next year.

> > > > Sinovac Biotech got listed on the NYSE Amex late in 2004, and had
> > > > planned for the transfer for long, but could not meet the market
> > > > requirements by NASDAQ due to its low share price, said Helen G Yang,
> > > > manager of the international business department at Sinovac Biotech.

> > > > When its shares started surging since early this year after the
> > > > outbreak of the H1N1 influenza, the company began to communicate with
> > > > the NASDAQ bourse in August, she said.

> > > > Since it started developing the H1N1 vaccine in early June, Sinovac's
> > > > share price has more than tripled during the past five months, from
> > > > around $2. On Tuesday, its stock closed at $7.91.

> > > > Compared with their share prices three months ago, the Hualan
> > > > Biological Engineering and Tiantan Biological shares had risen by 200
> > > > and 150 percent, respectively, at the end of October.

> > > > During the roadshow in late September, Sinovac was warmly welcomed by
> > > > the NASDAQ market. "I felt so surprised to see the strong recognition
> > > > of a Chinese vaccine producer," said Yin.

> > > > "The H1N1 flu and Sinovac's good performance during the outbreak have
> > > > increased the speed of its transfer to the NASDAQ."

> > > > Sinovac Biotech, established in 2001, was the first company in the
> > > > world to announce preliminary clinical trials of the vaccine and the
> > > > first to get approval for production from the Chinese government in
> > > > late August.

> > > > The company has won three orders for 11.49 million people, the second
> > > > largest supplier after Hualan Biological among the eight Chinese H1N1
> > > > flu vaccine producers.

> > > > As on Nov 1, the Chinese mainland had reported 47,500 H1N1 cases in 31
> > > > provinces and regions. It is estimated that 390 million Chinese need
> > > > to get vaccinated, but the nation had only ordered vaccines for 70
> > > > million people until October.

> > > > Sinovac said it expected to get more orders, and was speeding up
> > > > production, but "the benefits from the H1N1 flu vaccine are short-
> > > > term. What we are targeting is to become a leading vaccine producer
> > > > worldwide by leveraging our growing brand awareness," Yin said.

> > > > China is now the third largest vaccine market with a size of $1
> > > > billion annually.

> > > > On Nov 5, 6:58 pm, wittle <jinsant...@gmail.com> wrote:

> > > > > There has to be some added incentives, tax credits, low interest
> > > > > loans, additional payment for development cost, given to SVA by the
> > > > > government. I've heard this $3 number, the price of two tootsie rolls.
> > > > > I don't believe that number will be validated in the end. Just making
> > > > > and moving the empty vials would cost $3 and the Chinese  gov. would
> > > > > never force a company to run in the red. No, SVA will probably be
> > > > > rewarded with free land and a new facility, besides a bunch of medals,
> > > > > for their heroic efforts.

> > > > > On Nov 5, 5:32 pm, tickerwatch <aileenn...@gmail.com> wrote:

> > > > > > The Chinese govt is paying around $3 per shot, and the calculation
> > > > > > should be based on doses already delivered(not 65 million). I wonder
> > > > > > if SVA is going to take the hit for the development cost of the drug
> > > > > > upfront or accrue it till year-end.  That would certain have an impact
> > > > > > on the profitability for the quarter.

> > > > > > On Nov 6, 7:58 am, wittle <jinsant...@gmail.com> wrote:

> > > > > > > So if Hong Kong is paying $10 a dose for 3 million doses and Sinovac
> > > > > > > is supplying 65 million doses of h1n1 vaccine to the Chinese Gov.,
> > > > > > > with tax credits, that equals 65 million x $10 and an unbelievable 650
> > > > > > > million dollars. Their previous revenue guidance was revised up from
> > > > > > > 60 million dollars to an "unknown" figure. The 60 million was
> > > > > > > previously revised up from 22 million. On Q2 SVA's return on equity
> > > > > > > was 17.7%. Reuters has projected an EPS of .07 cents for Q3. Q2's EPS
> > > > > > > was .14. Is my belief an EPS of .49 for Q3 realistic? If someone comes
> > > > > > > up with a more exact EPS guess, I'd like to see it. The unknown is how
> > > > > > > many doses of h1n1 will SVA receive payment for in this quarter. I
> > > > > > > believe a partial order payment was paid by the Chinese Gov. for the
> > > > > > > 65 million doses ordered and the remaining (70%?) will be paid upon
> > > > > > > delivery. So a ballpark guess is 50% of the revenue on 65 million
> > > > > > > doses will be reported this quarter.

> > > > > > > On Nov 5, 3:50 pm, David <david.dodd...@gmail.com> wrote:

> > > > > > > > For your information...

> > > > > > > >http://www.reuters.com/article/marketsNews/idCNSP7332220091105?rpc=44...

> > > > > > > - Show quoted text -- Hide quoted text -

> > - Show quoted text -